Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 6/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3986065 | 1.00 | HRH3 (0.32) | HRH3HTR4USP2ALDH1A1LMNA | |
| SCHEMBL1022505 | 0.90 | HTR4 (0.37) | HTR4 | |
| SCHEMBL1021565 | 0.90 | HTR4 (0.37) | HTR4 | |
| SCHEMBL2980596 | 0.90 | HTR4 (0.37) | HTR4 | |
| SCHEMBL1022503 | 0.90 | HTR4 (0.37) | HTR4 | |
| SCHEMBL3983380 | 0.87 | KDM4E (0.38) | USP2ALDH1A1LMNA | |
| SCHEMBL3986069 | 0.87 | KDM4E (0.38) | USP2ALDH1A1LMNA | |
| SCHEMBL2975908 | 0.84 | PIK3CD (0.37) | USP2ALDH1A1 | |
| SCHEMBL2975909 | 0.84 | PIK3CD (0.37) | USP2ALDH1A1 | |
| SCHEMBL2965770 | 0.84 | PIK3CD (0.37) | USP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807423-B1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2009-05-20 | — | — | EP | claimed |
| US-7498442-B2 | Quinolinone-carboxamide compounds | THERAVANCE, INC. (US) | 2009-03-03 | — | — | US | claimed |
| US-20080167295-A1 | Containing a nortropane ring, e.g., 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[2-hydroxy-3-(4-methanesulfonylpiperazin-1-yl)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide; 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-07-10 | — | — | US | claimed |
| US-7396933-B2 | Quinolinone-carboxamide compounds | THERAVANCE, INC. (US) | 2008-07-08 | — | — | US | claimed |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | THERAVANCE, INC. | 2006-05-11 | — | — | US | claimed |
| EP-1807423-B1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2009-05-20 | — | — | EP | disclosed |
| US-7498442-B2 | Quinolinone-carboxamide compounds | THERAVANCE, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20080167295-A1 | Containing a nortropane ring, e.g., 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[2-hydroxy-3-(4-methanesulfonylpiperazin-1-yl)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide; 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-07-10 | — | — | US | disclosed |
| US-7396933-B2 | Quinolinone-carboxamide compounds | THERAVANCE, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | THERAVANCE, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167295-A1 | Containing a nortropane ring, e.g., 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[2-hydroxy-3-(4-methanesulfonylpiperazin-1-yl)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide; 5-HT4 receptor agonists | HTR5A, HTR4, HTR1A | HRH3 178/4885HTR4 2/4885USP2 3473/4885 |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | HTR4, HTR5A, HTR2C | HRH3 169/4885HTR4 1/4885USP2 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.